Skip to main content
Hauptrubriken
Zeitschriften Fortbildung Hebammen Bücher Kongresse & Live-Webinare
Social Media - Folgen Sie uns!
Instagram Facebook LinkedIn Instagram Hebammen
Service
Jobbörse Kundenservice Info & Hilfe
Fokus-Themen
Chronisch-entzündliche Darmerkrankung COVID-19-Update Diabetes Hautpflege Klima & Gesundheit Hygiene Intensivpflege Kardiologische Pflege Mobilisation Nachhaltigkeit Nierenerkrankungen Obstipation Onkologische Pflege Palliativpflege Schmerz Sucht in der Pflege Vielfalt, Gleichberechtigung und Inklusion Wundversorgung
Erweiterte Suche
Anmelden
nach oben
Zeitschrift für Gerontologie und Geriatrie
Erschienen in:

01.06.2014 | Beiträge zum Themenschwerpunkt

Influence of central nervous system-acting drugs on results of cognitive testing in geriatric inpatients

verfasst von: M. Gogol, H. Hartmann, S. Wustmann, A. Simm

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Growing evidence shows a high correlation between extensive use of central nervous system-acting drugs (CNSADs) in elderly patients and adverse drug reactions (ADRs) such as falls, fractures, and mortality.

Research question

Are results of cognitive testing with the Mini Mental Status Examination (MMSE) influenced by use of CNSADs?

Setting

Geriatric inpatient service for acute, subacute, and rehabilitation care.

Methods

Secondary combined analysis of two prospective, single-center study cohorts (PROPSYC, 2011 and AGE OUT, 2012) with identical procedure for the MMSE at a tertiary hospital.

Results

Overall, 395 patients were included, 144 male (M) and 251 female (F). Mean age was 80.0 ± 8.4 years (M 76.7 ± 9.1, F 81.9 ± 7.3, p = 0.0000). Mean MMSE points were 22.9 ± 4.8 (M 23.2 ± 4.6, F 22.6 ± 5.0, p = 0.211). In total, 258 patients (65.3 %) used drugs with potential adverse cognitive properties. Analgesics with central activity were given to 117 of 395 patients (29.6 %). Low-potency opioids (tramadol hydrochloride, tilidine) were identified in 60 patients and high-potency opioids in 57 patients. Antidepressants were used in 66 patients, benzodiazepines in 26, and hypnotics in 11, while 38 patients received other CNSADs. We only found significant correlations with the results of cognitive testing for sedatives (diazepam and oxazepam, Pearson’s r − 0.79, p = 0.05), but not for lorazepam.

Conclusion

Our analysis shows an influence of sedatives (diazepam and oxazepam, but not lorazepam) on cognitive testing with the MMSE in users of CNSADs.
Vorheriger Artikel Medikamentöse Therapie im Alter
Nächster Artikel Design of pharmaceutical products to meet future patient needs requires modification of current development paradigms and business models
Literatur
1.
Folstein MF, Folstein SE, McHugh PR (1975) “Mini Mental State”: a practical method for grading the cognitive state of patients for clinician. J Psychiatr Res 12:189–198CrossRefPubMed
2.
Le Quintrec JL, Bussy C, Golmard JL et al (2005) Randomized controlled drug trials on very elderly subjects: descriptive and methodological analysis of trials published between 1990 and 2002 and comparison with trials on adults. J Gerontol 60A:340–344
3.
4.
Teno JM, Weitzen S, Wetle T, Mor V (2001) Persistent pain in nursing home residents. JAMA 285:2081CrossRefPubMed
5.
Elliot AM, Smith BH, Penny KI et al (1999) The epidemiology of chronic pain in the community. Lancet 354:1248–1252CrossRef
6.
Hardt R (2007) Der ältere Schmerzpatient in der Praxis, 2. Aufl. ComMed medizinischer Verlag, Schopfheim
7.
American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons (2009) Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 57:1331–1346CrossRef
8.
Gloth III FM (2011) Pharmacological management of persistent pain in older persons: focus on opioids and nonopioids. J Pain 12(Suppl 1):S14–S20CrossRefPubMed
9.
Reisner L (2011) Pharmacological management of persistent pain in older persons. J Pain 12(Suppl 1):S21–S29CrossRefPubMed
10.
Pergolizzi J, Böger RH, Budd K et al (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (burprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8:287–313CrossRefPubMed
11.
Liukas A, Kuusniemi K, Aantaa R et al (2008) Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther 84:462–467CrossRefPubMed
12.
Berde C, Nurko S (2008) Opioid side effects—mechanism-based therapy. N Engl J Med 358:2400–2402CrossRefPubMed
13.
14.
Papaleontiou M, Henderson CR Jr, Turner BJ, Moore AA et al (2010) Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis. J Am Geriatr Soc 58:1353–1369CrossRefPubMedCentralPubMed
15.
Etzioni S, Chodosh J, Ferrell BA, MacLean CH (2007) Quality indicators for pain management in vulnerable elders. J Am Geriatr Soc 55(Suppl 2):S403–S408CrossRefPubMed
16.
Kuehn BM (2010) Alarming nonfatal overdose rates found for opioids, sedatives, and tranquilizers. JAMA 303:2020–2021CrossRefPubMed
17.
Dunn KM, Saunders KW, Rutter CM et al (2010) Opioid prescriptions for chronic pain and overdose. A cohort study. Ann Intern Med 151:85–92CrossRef
18.
Von Korff M, Kolodny A, Deyo RA, Chou R (2011) Long-term opioid therapy reconsidered. Ann Intern Med 155:325–328CrossRef
19.
Centers for Disease Control and Prevention (CDC) (2010) Emergency department visits involving nonmedical use of selected prescription drugs—United States, 2004–2008. MMWR Morb Mortal Wkly Rep 59:705–709
20.
Woodcock J (2009) A difficult balance—pain management, drug safety, and the FDA. N Engl J Med 361:2105–2107CrossRefPubMed
21.
22.
Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365:2002–2012CrossRefPubMed
23.
Solomon DH, Rassen JA, Glynn RJ et al (2010) The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 170:1968–1978CrossRefPubMed
24.
Solomon DH, Rassen JA, Glynn RJ et al (2010) The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 170:1979–1986CrossRefPubMed
25.
Buckeridge D, Huang A, Hanley J et al (2010) Risk of injury associated with opioid use in older adults. J Am Geriatr Soc 58:1664–1670CrossRefPubMed
26.
Miller M, Stürmer T, Azrael D et al (2011) Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc 59:430–438CrossRefPubMedCentralPubMed
27.
Meuleners LB, Duke J, Lee AH et al (2011) Psychoactive medications and crash involvement requiring hospitalizations for older drivers: a population-based study. J Am Geriatr Soc 59:1575–1580CrossRefPubMed
28.
Gomes T, Redelmeier DA, Juurlink DN et al (2013) Opioid dose and risk of road trauma in Canada: a population-based study. JAMA Intern Med 173:196–201CrossRefPubMed
29.
Wolf BC, Lavezzi WA, Sullivan LM, Flannagan LM (2005) One hundred seventy deaths involving the use of oxycodone in Palm Beach County. J Forensic Sci 50:192–195PubMed
30.
Okie A (2010) A flood of opioids, a rising tide of deaths. N Engl J Med 361:1981–1985CrossRef
31.
Centers for Disease Control and Prevention (CDC) (2009) Overdose deaths involving prescription opioids among Medicaid enrollees—Washington, 2004–2007. MMWR Morb Mortal Wkly Rep 58:1171–1175
32.
Hall AJ, Logan JE, Toblin RL et al (2008) Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 300:2613–2620CrossRefPubMed
33.
Bohnert AS, Valenstein M, Bair MJ et al (2011) Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 305:1315–1321CrossRefPubMed
34.
Gomes T, Mamdani MM, Dhalla IA et al (2011) Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 171:686–691PubMed
35.
Gwira Baumblatt JA, Wiedemann C, Dunn JR et al (2014) High-risk use by patients prescribed opioids for pain and the role in overdose death. JAMA Intern Med. doi:10.1001/jamainternmed.2013.12711
36.
Jena AB, Goldman D, Weaver L, Karaca-Mandic P (2014) Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims. BMJ 348:g1393CrossRefPubMedCentralPubMed
37.
Simoni-Wastila L, Yang HK (2006) Psychoactive drug abuse in older adults. Am J Geriatr Pharmacother 4:380–394CrossRefPubMed
38.
Lakey SL, Gray SL, Sales AEB et al (2006) Psychotropic use in community residential care facilities: a prospective cohort study. Am J Geriatr Pharmacother 4:227–235CrossRefPubMed
39.
Barton C, Sklenicka J, Sayegh P, Yaffe K (2008) Contraindicated medication use among patients in a memory disorders clinic. Am J Geriatr Pharmacother 6:147–152CrossRefPubMed
40.
Rikala M, Korhonen MJ, Sulkava R, Hartikainen S (2011) Psychotropic drug use in community-dwelling elderly people—characteristics of persistent and incident users. Eur J Clin Pharmacol 67:731–739CrossRefPubMed
41.
Kashyap M, Belleville S, Mulsant BH et al (2014) Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline. J Am Geriatr Soc 62:336–341CrossRefPubMed
42.
Lechevallier-Michel N, Molimard M, Dartigues J-F et al (2004) Drugs with anticholinergic properties and cognitive decline performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol 59:143–151CrossRef
43.
Vigen CLP, Mack WJ, Keefe R et al (2011) Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry 168:831–839CrossRefPubMedCentralPubMed
44.
Rosenberg PB, Mielke MM, Han D et al (2012) The association of psychotropic medication with the cognitive, functional, and neuropsychiatric trajectory of Azheimer’s disease. Int J Geriatr Psychiatry 27:1248–1257CrossRefPubMedCentralPubMed
45.
Wright RM, Roumani YF, Boudreau R et al (2009) Effect of central nervous system medication use on decline in cognition in community-dwelling older adults: findings from the Health, Aging and Body Composition study. J Am Geriatr Soc 57:243–250CrossRefPubMedCentralPubMed
46.
Puustinen J, Nurminen J, Vahlberg T et al (2012) CNS medications as predictors of precipitous cognitive decline in the cognitively disabled aged: a longitudinal population-based study. Dement Geriatr Cogn Dis Extra 2:57–68CrossRefPubMedCentralPubMed
47.
Maust DT, Oslin DW, Marcus C (2014) Effect of age on the profile of psychotropic users: results from the 2010 National Ambulatory Medical Care Survey. J Am Geriatr Soc 62:358–364CrossRefPubMed
48.
Rossi MI, Young A, Maher R et al (2007) Polypharmacy and health beliefs in older outpatients. Am J Geriatr Pharmacother 5:317–323CrossRefPubMed
49.
Hanlon JT, Wang X, Castle NG et al (2011) Potential underuse, overuse, and inappropriate use of antidepressants in older veteran nursing home residents. J Am Geriatr Soc 59:1412–1420CrossRefPubMedCentralPubMed
50.
Porsteinsson AP, Drye LT, Pollock GB et al (2014) Effect of citalopram on agitation in Alzheimer disease. The CitAD randomized clinical trial. JAMA 311:682–691CrossRefPubMedCentralPubMed
51.
Caballero J, Hitchcock M, Beversdorf D et al (2006) Long-term effects of antidepressants on cognition in patients with Alzheimer’s disease. J Clin Pharm Ther 31:593–598CrossRefPubMed
52.
Savaskan E, Müller SE, Böhringer A et al (2008) Antidepressive therapy with escitalopram improves mood, cognitive symptomes, and identify memory for angry faces in elderly depressed patients. Int J Neuropsychopharmacol 11:381–388CrossRefPubMed
53.
Rozzini L, Chilovi BV, Conti M et al (2010) Efficacy of SSRIs on cognition of Alzheimer’s disease patients treated with cholinesterase inhibitors. Int Psychogeriatr 22:114–119CrossRefPubMed
54.
Podewils LJ, Lyketsos CG (2002) Tricyclic antidepressants and cognitive decline. Psychosomatics 43:31–35CrossRefPubMed
55.
Potvin O, Forget H, Grenier S et al (2011) Anxiety, depression, and 1-year incident cognitive impairment in community-dwelling older adults. J Am Geriatr Soc 59:1421–1428CrossRefPubMed
56.
Caballero J, Hitchcock M, Scharre D et al (2006) Cognitive effects of atypical antipsychotics in patients with Alzheimer’s disease and comorbid psychiatric or behavioral problems: a retrospective study. Clin Ther 28:1695–1700CrossRefPubMed
57.
Foy A, O’Connell D, Henry D, Kelly J et al (1995) Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients. J Gerontol 50A:M99–M106CrossRef
58.
Desplenter F, Lavikainen P, Hartikainen S et al (2012) Sedative use and incident cognitive decline among persons aged 75 years and older: a population-based longitudinal study. Int Psychogeriatr 24:48–54CrossRefPubMed
59.
Puustinen J, Nurminen J, Kukola M et al (2007) Associations between use of benzodiazepines or related drugs and health, physical abilities and cognitive function: a non-randomised clinical study in the elderly. Drugs Aging 24:1045–1059CrossRefPubMed
60.
61.
Allen RS, Thorn BE, Fisher SE et al (2003) Prescription and dosage of analgesic medication in relation to resident behaviors in the nursing home. J Am Geriatr Soc 51:534–538CrossRefPubMedCentralPubMed
62.
Closs SJ, Barr B, Briggs M (2004) Cognitive status and analgesic provision in nursing home residents. Br J Gen Pract 54:919–921PubMedCentralPubMed
63.
Kurita GP, Sjogren P, Ekholm O et al (2011) Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol 29:1297–1303CrossRefPubMed
64.
Puustinen J, Nurminen J, Löppönen M et al (2011) Use of CNS medications and cognitive decline in the aged: a longitudinal population-based study. BMC Geriatr 11:70CrossRefPubMedCentralPubMed
65.
Sjogren P, Christrup LL, Petersen MA, Hojsted J (2005) Neuropsychological assessment of chronic non-malignant pain patients treated in a multidisciplinary pain centre. Eur J Pain 9:453–462CrossRefPubMed
66.
Taipale HAT, Hartikainen S, Bell JS (2010) A comparison of four methods to quantify the cumulative effect of taking multiple drugs with sedative properties. Am J Geriatr Pharmacother 8:460–471CrossRefPubMed
67.
Boudreau RM, Hanlon JT, Roumani YF et al (2009) Central nervous system medication use and incident mobility limitation in communiy elders: the Health, Aging, and Body Composition Study. Pharmacepidemiol Drug Saf 18:916–922CrossRef
68.
Hanlon JT, Boudreau RM, Roumani YF et al (2009) Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition Study. J Gerontol 64A:492–498CrossRef
69.
Woolcott JC, Richardson KJ, Wiens MO et al (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952–1960CrossRefPubMed
70.
Leipzig RM, Cumming RG, Tinetti ME (1999) Drugs and falls in older people: a systematic review and meta-analysis: I. psychotropic drugs. J Am Geriatr Soc 47:30–39PubMed
71.
Vestergaard P, Prieto-Alhambra D, Javaid MK, Cooper C (2013) Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose. Osteoporos Int 24:671–680CrossRefPubMedCentralPubMed
72.
Vestergaard P, Rejnmark L, Mosekilde L (2006) Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17:807–816CrossRefPubMed
73.
Potvin O, Lorrain D, Forget H et al (2012) Sleep quality and 1-year incident cognitive impairment in communiy-dwelling older adults. Sleep 35:491–499PubMedCentralPubMed
74.
Jaussent I, Bouyer J, Ancelin M-L et al (2012) Excessive sleepiness is predictive of cognitive decline in the elderly. Sleep 35:1201–1207PubMedCentralPubMed
75.
Bonanni E, Maestri M, Tognoni G et al (2005) Daytime sleepiness in mild and moderate Alzheimer’s disease and its relationship with cognitive impairment. J Sleep Res 14:311–317CrossRefPubMed
76.
Merlino G, Piani A, Gigli GL et al (2010) Daytime sleepiness is associated with dementia and cognitive decline in older Italian adults: a population-based study. Sleep 11:372–377CrossRef
77.
Dzierzewski JM, Fung CH, Jouldjian S et al (2014) Decrease in daytime sleeping is associated with improvement in cognition after hospital discharge in older adults. J Am Geriatr Soc 62:47–53CrossRefPubMedCentralPubMed
78.
Khaw KT, Wareham N, Bingham S et al (2008) Combined impact of health behaviours and mortality in men and women: the EPIC-Norfolk prospective population study. PLoS Med 5:e12CrossRefPubMedCentralPubMed
79.
Elwood P, Galante J, Pickering J et al (2013) Healthy lifestyles reduce the incidence of chronic diseases and dementia: evidence from the Caerphilly cohort study. PLoS One 8:e8187CrossRef
80.
Crichton GE, Elias MF, Davey A, Alkerwi A (2014) Cardiovascular health and cognitive function: the Maine-Syracuse Longitudinal Study. PLoS One 9:e89317CrossRefPubMedCentralPubMed
81.
Macintosh BJ, Swardfager W, Crane DE et al (2014) Cardiopulmonary fitness correlates with regional cerebral grey matter perfusion and density in men with coronary artery disease. PLoS One 9:e91251CrossRefPubMedCentralPubMed
82.
Gow AJ, Bastin ME, Muñoz Maniega S et al (2012) Neuroprotective lifestyles and the aging brain: activity, atrophy, and white matter integrity. Neurology 79:1802–1808CrossRefPubMed
83.
Rebok GW, Ball K, Guey LT et al (2014) Ten-year effects of the advanced cognitive training for independent and vital Elderly Cognitive Training Trial on cognition and everyday functioning in older adults. J Am Geriat Soc 62:16–24CrossRefPubMedCentralPubMed
84.
Wayne PM, Walsh JN, Taylor-Piliae RE et al (2014) Effect of Tai Chi on cognitive performance in older adults: systematic review and meta-analysis. J Am Geriatr Soc 62:25–39CrossRefPubMedCentralPubMed
85.
Belleville S, Clément F, Mellah S et al (2011) Training-related brain plasticity in subjects at risk of developing Alzheimer’s disease. Brain 134:1623–1634CrossRefPubMed
86.
87.
Dunstan DW, Barr ELM, Healy GN et al (2010) Television viewing time and mortality. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Circulation 120:384–391CrossRef
88.
89.
Stessman J, Hammerman-Rozenberg R, Cohen A et al (2009) Physical activity, function, and longevity among the very old. Arch Intern Med 169:1476–1483CrossRefPubMed
90.
Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280–292CrossRefPubMedCentralPubMed
Metadaten
Titel
Influence of central nervous system-acting drugs on results of cognitive testing in geriatric inpatients
verfasst von
M. Gogol
H. Hartmann
S. Wustmann
A. Simm
Publikationsdatum
01.06.2014
Verlag
Steinkopff-Verlag
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 4/2014
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-014-0654-5

Weitere Artikel der Ausgabe 4/2014

Mitteilungen der ÖGGG

Polypharmazie und Arzneimitteltherapiesicherheit im Alter

  • Übersichten

Erratum to: Design of pharmaceutical products to meet future patient needs requires modification of current development paradigms and business models

  • Erratum

Mitteilungen der DGGG

Mitteilungen des Bundesverbands Geriatrie

Wohnmobilität im Alter

  • Originalien